We describe two patients with osteomyelitis due to Candida spp. treated with fluconazole, a new triazole antifungal. One patient had extensive involvement of ribs and costochondral regions of the anterior chest, and the other had vertebral infection. Both were cured with courses of 10 and 14 months, with greater than or equal to 1 year of follow-up after fluconazole was discontinued. Fluconazole is an attractive agent for the treatment of Candida osteomyelitis and deserves to be studied more extensively for this indication.